



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	307902	Melrose High Strength Fish Oil
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Melrose Laboratories Pty Ltd	
<b>Postal Address</b>	16-18 Lionel Rd, Mt Waverley, VIC, 3149 Australia	
<b>ARTG Start Date</b>	7/08/2018	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Melrose High Strength Fish Oil

Product Type	Single Medicine Product	Effective Date	7/08/2018
--------------	-------------------------	----------------	-----------

### Permitted Indications

- Helps maintain/support healthy eye development
- Maintain/support healthy eye function
- Maintain/support eye health
- Helps maintain/support eye retina health
- Helps maintain/support healthy vision development
- Maintain/support healthy eyesight/vision
- Maintain/support general health and wellbeing
- Helps in the maintenance of healthy blood lipids/blood fats
- Maintain/support cardiovascular system health
- Maintain/support healthy cardiovascular system function
- Maintain/support heart health
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
- Maintain/support cognitive function/mental function
- Maintain/support brain function
- Maintain/support nervous system health
- Maintain/support brain/central nervous system development
- Maintain/support nervous system function
- Maintains/support healthy foetal development

### Indication Requirements



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must not imply or refer to vision correction, faults or serious eye disease e.g. macular degeneration.

Product presentation must not imply or refer to serious cardiovascular conditions.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to lowering blood lipids, blood fats and triglycerides.

Label statement: If symptoms persist, talk to your health professional.

If directed to women, Label statement: Advise your doctor of any medicine you take during pregnancy, particularly in your first trimester.

Product presentation must not imply or refer to neurological conditions or developmental delays.

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

No Warnings included on Record

**Additional Product information**

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form** Oral Liquid

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

<b>concentrated fish Omega-3 triglycerides</b>	<b>950 mg/mL</b>
Equivalent: eicosapentaenoic acid	374 mg/mL
Equivalent: docosahexaenoic acid	187 mg/mL

**Other Ingredients (Excipients)**

**Flavour**

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary